Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 30 P54

BSPED2012 Poster Presentations (1) (66 abstracts)

Management of childhood-onset GH deficiency in young adulthood

Mahjouba Ahmid 1 , C G Perry 2 , M Donaldson 1 , S F Ahmed & M G Shaikh 1,


1Endocrine Service, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK; 2Department of Endocrinology, Western Infirmary, Glasgow, UK.


Background: GH therapy in adolescents with childhood onset GH deficiency (CO-GHD) is often necessary to prevent adult GHD syndrome and requires a re-evaluation of the GH axis on attainment of final height. Not all individuals with CO-GHD remain GH deficient and re-evaluation is required to confirm or refute adult GHD.

Aim: Review the care received by young adults diagnosed with CO-GHD.

Design: Retrospective review of young adults with CO-GHD patients between 2005 and 2011 in a single paediatric tertiary centre.

Result: 75 former CO-GHD patients, 48 male: 27 female, with median age 19 year (15–26.2) at time of data collection were reviewed. The etiologies of CO-GHD were: craniopharyngioma and other tumours (n=28), multiple pituitary hormone deficiencies (MPHD) (n=8), isolated GH deficiency (IGHD) (n=14), and other causes (n=25). Median age at diagnosis was 12.5 year (0.25–16.9) with initial GH peak 2.3 μg/l (0.1 – 6.5). Of 75 patients, only 66 were treated with GH at a median age 11.5year (1.2 –17.2), and 41 of those who received GH therapy were later referred to the transition clinic at a median age 17.9 year (16–20.7) for re-assessment the GH axis after withdrawal of GH therapy at a median age 16.4 year (10.6–20) with a median duration of treatment 4.5year (0.3–16.1). Re-evaluation of the GH axis was performed in 41 cases after 0.4 year (0.17–4.3) of GH withdrawal, median repeat GH peak 1.1 μg/l (0.1–7.9) of those 32 who remained GHD only 29 opted to restart GH therapy.

Conclusions: Optimal care of adults with CO-GHD requires a close relationship between paediatric and adult services. A substantial proportion of affected adults continue to have GHD and most opt for GH therapy. There is a need for a study of the current practice of assessment and management of CO-GHD in the UK.

Volume 30

40th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts